Last reviewed 2026-04-20 · How we verify

Ajovy (FREMANEZUMAB)

Ajovy works by blocking the action of calcitonin gene-related peptide 1 (CGRP1), a molecule involved in pain transmission.

At a glance

Mechanism of action

Fremanezumab-vfrm is humanized monoclonal antibody that binds to calcitonin gene-related peptide (CGRP) ligand and blocks its binding to the receptor.

Approved indications

• Migraine
• Prevention of migraine attacks

Common side effects

• Injection site reactions
• Injection site pain
• Induration
• Erythema
• Anaphylactic reactions
• Angioedema
• Anti-AJOVY neutralizing antibodies

Key clinical trials

• Fremanezumab Treatment of Migraine in Women With Menstrual Migraine Ages 18-45 (PHASE4)
• Fremanezumab, Migraine and Sleep (PHASE4)
• A Study to Test if Fremanezumab is Effective in Preventing Migraine in Children and Adolescents (PHASE3)
• A Study to Test if Fremanezumab is Effective in Preventing Chronic Migraine in Participants 6 to 17 Years of Age (PHASE3)
• A Randomized, Double-Blind, Placebo-Controlled Study With an Open-Label Period on Efficacy and Safety of Fremanezumab in Chinese Adults With Migraine (PHASE3)
• Migraine Medication Effects on Urinary Symptoms
• Study for Prevent Chronification Migraine Through Prediction of Response to Treatment With Anti-CGRP Antibodies
• Real-world Prospective Study on the Use of Anti-CGRP Drugs in Migraine

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

• Ajovy CI brief — competitive landscape report
• Ajovy updates RSS · CI watch RSS
• Teva portfolio CI